Deepaloke Chatterjee advises on all aspects of EU, UK and international competition law, including merger control, foreign investment, cartel and other types of anti-competitive business conduct investigations, abuse of dominance and technology regulation.
Deepaloke regularly represents clients on high-profile and complex transactions requiring Phase 1 or Phase 2 merger clearances, including from the UK's Competition and Markets Authority (CMA) and the European Commission (EC). Notably, Deepaloke has experience of negotiating merger remedies with multiple antitrust agencies. He recently completed an extended period on secondment to the CMA, where he worked on several key Phase 1 merger cases and gained first-hand insights into the CMA's approach, including by acting as the 'Devil's Advocate' on two Phase 1 cases.
Deepaloke has also advised on cartel and abuse of dominance investigations involving novel legal issues, and has represented clients before the CMA and the EC in oral hearings and during inspections.
Deepaloke advises major corporate enterprises, financial investors and their portfolio companies in a diverse range of industries such as pharmaceuticals, technology, financial services, and consumer goods & retail. Deepaloke publishes and speaks frequently on a variety of competition law topics. He is currently an Associate Editor of the European Health & Pharmaceutical Law Review, and a member of the judging panel for the International Moot Court Competition on Antitrust Law hosted annually by King's College London.
- A listed company on an ongoing EC cartel investigation in the consumer goods sector, including responding to a Statement of Objections and representation at an oral hearing
- Delivery Hero on successfully settling the EC's cartel investigation into food delivery services
- A US-listed company on the EC’s investigation into cross border trade restrictions, including representation at an EC inspection
- CVC Capital Partners and its portfolio companies on the merger control and foreign investment aspects of numerous deals in the pharmaceuticals sector, including notably Cooper Consumer Health's acquisition of Viatris' European OTC portfolio (EC Phase 1 remedies)
- Recursion Pharmaceuticals Inc. on its acquisition of Exscientia Plc. Further deals listed below
- CMA Experience (on secondment): acted as an Assistant Legal Director on Phase 1 mergers across a wide range of sectors.
News and client work
Contact details
Awards and citations
- Winner, Best Business Article
Concurrences Antitrust Writing Awards 2026 - Concerted Practices category, “The Signalling Effect: Assessing EU Antitrust Risk in Public Communications and Earnings Calls”